MOSCOW, 5 March – RIA Novosti. The Russian drug Sputnik V has risen to the second place among coronavirus vaccines in terms of the number of countries approving it, overtaking Pfizer, according to the official Twitter account of the vaccine.
The first place in the world in terms of the number of states that have agreed on the use of the drug is now occupied by the AstraZeneca vaccine, licensed in 49 countries, followed by Sputnik V with 45 countries. Pfizer ranks third (43 countries). This is followed by the Moderna vaccine (19 countries), as well as three Chinese vaccines – Sinopharm (18), Sinovac (16), CanSino (4). The Johnson & Johnson vaccine is in eighth place, it has been approved by 4 countries.
#SputnikV is now the world's second most popular #CovidVaccine in terms of regulatory approvals. Thank you for this vote of confidence! pic.twitter.com/dYYqLYUYs8
– Sputnik V (@sputnikvaccine) March 5, 2021
Currently, Sputnik V has been approved for use in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska ( Entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Djibouti, Republic of Congo, Sri Lanka, Laos and Iraq.
The total population of 45 countries in which the Sputnik V vaccine is registered exceeds 1.2 billion.
Expertise in the EU
On the eve of the European Medicines Agency (EMA) began an examination of the registration dossier of the Sputnik V coronavirus vaccine – the drug is checked for compliance with EU standards for efficacy and quality.
At the same time, the regulator said that they intend to conduct an assessment in a shortened time, but the exact date was not named.
Earlier, Hungary and Slovakia approved the use of “Sputnik V” without waiting for the pan-European registration. According to surveys, the Russian drug is one of the most demanded vaccines in Europe. A study by the Institute for Management and Economic Research of Austria (IMWF Austria) shows that the inhabitants of this country have more confidence in Sputnik V than in the AstraZeneca vaccine.
The Ministry of Health registered the Sputnik V vaccine in August 2020, it was developed by the Gamaleya Research Center for Electrochemistry. This vaccine was the first in the world to prevent COVID-19. The scientific journal Lancet previously published the results of the third phase of clinical trials of the drug, confirming its high efficacy and safety.